Literature DB >> 12118171

Lyme arthritis and post-Lyme disease syndrome.

Arthur Weinstein1, Michael Britchkov.   

Abstract

In the United States, intermittent or chronic mono- or oligoarthritis, particularly affecting the knee, is the most common manifestation of late Lyme disease (LD). Lyme arthritis (LA) can usually be prevented by early treatment of acute LD. However, the erythema migrans rash may go undetected in children and in the dark skin of African Americans, leading to delayed treatment and a relatively increased incidence in LA. Virtually all untreated patients with LA have high levels of serum immunoglobulin G antibodies, and sometimes low levels of immunoglobulin M antibodies, to Borrelia burgdorferi (Bb) by ELISA and Western blot. These responses may persist for many years after antibiotic treatment, and therefore, serologic results do not accurately distinguish between active or past infection. Most patients with LA respond well to standard courses of antibiotic treatment, but a small percentage have persistent knee synovitis, in some cases possibly related to the triggering of intrasynovial autoimmunity. Other patients develop a syndrome of diffuse arthralgia, myalgia, fatigue, and subjective cognitive difficulty during or soon after LD, which persists despite antibiotic treatment. Patients with this post-treatment, post-LD syndrome were recently studied in a placebo-controlled double-blind antibiotic trial. There was no evidence of Borrelial infection in these patients by culture or detection of Bb DNA in blood or spinal fluid. Furthermore, there was no difference in responsiveness of these patients to a 3-month course of antibiotic compared with placebo treatment. Thus, LA caused by active Bb infection, post-treatment LA with persistent knee synovitis and post-LD syndrome are distinct and distinguishable clinical entities.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118171     DOI: 10.1097/00002281-200207000-00008

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  8 in total

1.  Lymelight: forecasting Lyme disease risk using web search data.

Authors:  Adam Sadilek; Yulin Hswen; John S Brownstein; Evgeniy Gabrilovich; Shailesh Bavadekar; Tomer Shekel
Journal:  NPJ Digit Med       Date:  2020-02-04

2.  Role of glutathione metabolism in host defense against Borrelia burgdorferi infection.

Authors:  Mariska Kerstholt; Hedwig Vrijmoeth; Ekta Lachmandas; Marije Oosting; Mihaela Lupse; Mirela Flonta; Charles A Dinarello; Mihai G Netea; Leo A B Joosten
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-14       Impact factor: 11.205

3.  Persistent synovitis in children with Lyme arthritis: two unusual cases. An immunogenetic approach.

Authors:  Guy Hendrickx; Hugo De Boeck; Anita Goossens; Christian Demanet; Yvan Vandenplas
Journal:  Eur J Pediatr       Date:  2004-07-28       Impact factor: 3.183

4.  Generalizability in two clinical trials of Lyme disease.

Authors:  Daniel J Cameron
Journal:  Epidemiol Perspect Innov       Date:  2006-10-17

5.  The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome.

Authors:  Alison W Rebman; Kathleen T Bechtold; Ting Yang; Erica A Mihm; Mark J Soloski; Cheryl B Novak; John N Aucott
Journal:  Front Med (Lausanne)       Date:  2017-12-14

6.  Ultrasound-guided hip arthrocentesis in a child with hip pain and Fever.

Authors:  James H Moak; Aaron J Vaughan; Benjamin A Silverberg
Journal:  West J Emerg Med       Date:  2012-09

7.  The Functional and Molecular Effects of Doxycycline Treatment on Borrelia burgdorferi Phenotype.

Authors:  John R Caskey; Nicole R Hasenkampf; Dale S Martin; Vladimir N Chouljenko; Ramesh Subramanian; Mercedes A Cheslock; Monica E Embers
Journal:  Front Microbiol       Date:  2019-04-18       Impact factor: 5.640

8.  Lymelight: forecasting Lyme disease risk using web search data.

Authors:  Adam Sadilek; Yulin Hswen; John S Brownstein; Evgeniy Gabrilovich; Shailesh Bavadekar; Tomer Shekel
Journal:  NPJ Digit Med       Date:  2020-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.